Fig. 6: Gut microbiome analysis of baseline fecal samples. | Nature Communications

Fig. 6: Gut microbiome analysis of baseline fecal samples.

From: Nivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trial

Fig. 6

A The Observed species of gut microbiota between responders (n = 12) and non-responders (n = 28). B Principal component analysis plot based on Metagenome sequencing of the fecal content from responders (n = 12) and non-responders (n = 28). C Component proportion of bacterial phylum in each group. D Comparison of relative abundance of bacterial genus level between responders (n = 12) and non-responders (n = 28). E Heat map of differentially abundant taxa in intestinal type (n = 16) vs non-intestinal type (n = 21), responders (n = 10) vs non-responders (n = 27), PFS ≥ 4 (n = 19) vs <4 months (n = 18). R responders; NR non-responders; PFS Progression-Free Survival; OS Overall Survival. All tests were two-sided for statistical evaluation. No adjustments for multiple comparisons were made. Each box plot shows the median as the central line, with the box boundaries representing the first and third quartiles (25th and 75th percentiles), and the whiskers indicating the range from minimum to maximum values. Source data are provided as a Source Data file.

Back to article page